EP
DFTX

Essential Partners’s Definium Therapeutics DFTX Stock Holding History

Essential Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.82K Buy
60
+39
+186% +$964 ﹤0.01% 1823
2026
Q1 		$397 Hold
21
– – ﹤0.01% 2500
2025
Q4 		$281 Buy
21
+17
+425% +$210 ﹤0.01% 2358
2025
Q3 		$47 Hold
4
– – ﹤0.01% 2572
2025
Q2 		$26 Buy
+4
New +$26 ﹤0.01% 2205

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Essential Partners's DFTX Position: Q2 2026 in Review

Essential Partners increased its Definium Therapeutics (DFTX) stake by 186% in Q2 2026, buying an estimated $964 and bringing the position to 60 shares worth $2.82K. The position accounts for ﹤0.01% of the portfolio, ranked #1823.

Essential Partners first reported a position in DFTX in Q2 2025 and has held it in 5 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Essential Partners held 60 shares of Definium Therapeutics worth $2.82K as of Q2 2026.
  • Essential Partners bought 39 Definium Therapeutics shares in Q2 2026, an estimated $964.
  • Definium Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1823 holding.
  • Essential Partners first reported a position in Definium Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.